Description: This three-part series provides an overview of the rapidly evolving and dynamic gene and cellular therapy landscape, from the clinical, historical, and risk transfer perspectives. It covers the actuarial considerations in pricing cell and gene insurance and reinsurance, the value assessment of the therapies, manufacturer pricing, and reinsurance cost.

Description: This three-part series provides an overview of the rapidly evolving and dynamic gene and cellular therapy landscape, from the clinical, historical, and risk transfer perspectives. It covers the actuarial considerations in pricing cell and gene insurance and reinsurance, the value assessment of the therapies, manufacturer pricing, and reinsurance cost.

Description: Some new variable and index-linked annuities offer simplified guarantees with limited downside protection; the policyholder “pays” for this protection with a limited upside. These products effectively provide policyholders access to an equity index with an option pass-through. This new direction blurs the line between more traditional variable annuity and fixed indexed annuity products. This session will discuss these and other similar product innovations, including some interesting regulatory, accounting, and risk management considerations.